ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0756

Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative
Abstract Number: 0250

Validation of Singe-Shot Computational Polarized Microscopy for Crystal Analysis of Synovial Fluid
Abstract Number: 1545

Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis
Abstract Number: 0357

Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting
Abstract Number: 1228

Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Abstract Number: 1958

Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study
Abstract Number: 1839

Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting
Abstract Number: 1840

Value of Various Intra-Articular Injections for Knee Osteoarthritis Management
Abstract Number: 2050

Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Abstract Number: 1996

Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics
Abstract Number: 0267

Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists
Abstract Number: 1305

Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis
Abstract Number: 1061

Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Abstract Number: 1443

Vasculitis Associations Among Patients with Systemic Lupus Erythematous
Abstract Number: 0229

Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].